Bayer and VUMC Partner to Advance Cardiovascular and Kidney Therapies
The collaboration will focus initially on cardiovascular and kidney diseases, combining Bayer’s drug development expertise with Vanderbilt University Medical Center’s extensive data resources to generate data-driven insights and accelerate the discovery and development of new therapies addressing significant unmet medical needs.
Juergen Eckhardt | 21/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy